Abstract
A prospective observational study was conducted to evaluate the prophylactic management of Deep Vein Thrombosis (DVT) in 60 patients admitted to the Intensive Care Unit of a tertiary care hospital. The study population included patients with diverse clinical conditions including orthopedic surgeries, cerebrovascular accidents, respiratory conditions, and post-operative cases. The mean age of patients was 59.8 years, with a gender distribution of 48.3% males and 51.7% females. Low Molecular Weight Heparin (LMWH), primarily Clexane (enoxaparin), was the most frequently prescribed prophylactic agent (68.3%), followed by Dabigatrol (20%), and unfractionated Heparin (5%). The standard dosing pattern observed was 0.4ml for Clexane and 220mg for Dabigatrol. The duration of prophylaxis ranged from 1 to 10 days, with an average duration of 5.4 days. Total knee replacement patients consistently received prophylaxis for 6 days. No adverse effects were reported during the study period, and no cases of DVT were documented. This study showed consistent prophylaxis patterns for specific conditions, particularly in orthopedic cases
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call